Pharmaceutical

Otsuka wins FDA breakthrough therapy designation for IgAN drug 

This positive news comes after Otsuka’s Phase III Alzheimer’s agitation trial failed to meet its primary endpoint, announced earlier this week.

Feb 16, 2024 - 18:00
Otsuka wins FDA breakthrough therapy designation for IgAN drug 
This positive news comes after Otsuka’s Phase III Alzheimer’s agitation trial failed to meet its primary endpoint, announced earlier this week.
Read the original article

Tags:

Previous Article

Sarepta’s Elevidys makes advances towards expanded DMD label

Next Article

QBiotics wins FDA orphan status for rainforest-derived cancer drug

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Ipilimumab by Bristol-Myers Squibb for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Ipilimumab by Bristol-Myers Squibb for Metastatic Trans...

Aug 30, 2023

Morning Rounds: Preterm birth rates vary across the U.S., with the highest in the Southeast

Morning Rounds: Preterm birth rates vary across the U.S...

Dec 11, 2023

STAT+: Drug companies and pharmacies reach $17.3 billion settlement over opioid crisis

STAT+: Drug companies and pharmacies reach $17.3 billio...

Jun 10, 2023